Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla on May 13 reported a 30 percent on-year jump in net profit to Rs 1,222 crore for the fourth quarter of the financial ...

Cipla MD Umang Vohra assured that the US government's directive to lower prescription drug costs will not impact Indian ...

Pharma giant Cipla announced a significant 30 percent increase in consolidated net profit attributable to shareholders for ...

The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Results: Cipla reported a 30.12% year-on-year increase in Q4FY25 net profit, reaching ₹1,221.84 crore, up from ₹939.04 crore.

Cipla, the third-largest pharmaceutical company in India by revenue, reported a fourth-quarter profit that exceeded ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...